This press release contains forward -looking statements.

Actual results may set from those set in this release due to the risks and uncertainties in our business, including difficulties or delays in development, initiation and execution of clinical trials, the results of clinical trials and the impact of those results and conduct of and conduct of subsequent studies and issues arising in the regulatory process;, achieving our collaboration and license agreement objectives and obtaining regulatory approval, the scope and validity of patent protection and the possibility of claims against us on the patent rights of others basis, our ability to obtain additional financing to support our operations, and other risks in the Risk Factors in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

– the ongoing multi center Phase 3 study in Canada to include seven locations in Germany as planned – A U.S. Study is enrolling subjects The data from the to 55. The data from the U.S. Study, and the Phase 3 clinical trials in Canada and Europe, and subsequent lot – to-lot consistency studies will contribute to a safety database of approximately 4,000 subjects for a planned BLA submission in 2008. – – to – lot consistency study comparing three consecutive many HEPLISAV Dynavax made in Europe and in the second half in the second half of the year in the U.S., Canada and Germany.Functions balloon kyphoplasty to vertebral fractures Treat; assessment calls for more research and systematic approach to the osteoporosis management.